Background {#S0001}
==========

Gastroesophageal reflux disease (GERD) comprises a spectrum of clinical presentations in which gastric content refluxes into the esophagus cause troublesome symptoms with or without visible damage to the esophageal mucosa.[@CIT0001] It is a common clinical disorder with an estimated prevalence of 9--28% in Europe and North America, and 5--18% in Asia.[@CIT0002],[@CIT0003] Proton pump inhibitor (PPI) is highly efﬁcacious in providing symptomatic relief, healing erosions and improving quality of life in patients with GERD,[@CIT0004] but there are still unmet clinical needs. The recent study has shown that prolonging PPI therapy from 4 weeks to 8 weeks does not increase the symptom response rate, however, reduces symptom relapse in patients with Los Angeles grade A or B erosive esophagitis.[@CIT0005]

PPI-refractory GERD refers to patients with symptoms of GERD who do not respond, or only partially respond, to therapy. The definition of refractory GERD is controversial, however, according to the Asia-Pacific consensus on the management of GERD, it may be defined as persistent and troublesome GERD symptoms unresponsive to at least 8 weeks of a standard dose of PPI.[@CIT0006] Several mechanisms have been proposed for the pathogenesis of refractory GERD, including weakly acidic reflux, delayed gastric emptying and concomitant functional bowel disorders.[@CIT0007]

The prokinetic agent cisapride, which is a 5HT-4 receptor agonist, was previously shown to have a synergistic effect with PPI on maintenance therapy for reﬂux esophagitis,[@CIT0008] but it has been found to be associated with potentially fatal heart arrhythmia. However, mosapride, which is also a 5-HT4 receptor agonist, is an alternative prokinetic agent that can be safely used in patients with various gastrointestinal disorders.[@CIT0009],[@CIT0010] It acts by increasing acetylcholine release from parasympathetic nerve endings and stimulating esophageal motility as well as gastric emptying.[@CIT0011],[@CIT0012] A previous study reported that mosapride with pantoprazole combination therapy was more effective than pantoprazole monotherapy in providing symptomatic relief to patients with erosive GERD, but that it offered no benefit over pantoprazole monotherapy in non-erosive reflux disease (NERD) patients.[@CIT0013] Another study of PPI-refractory patients found that administration of mosapride in addition to omeprazole improved gastroesophageal reﬂux symptoms and gastric emptying in PPI-refractory NERD patients with delayed gastric emptying, determined by the^13^C-acetate breath test.[@CIT0012]

A recent systematic review aimed at assessing the potential benefits of mosapride plus PPI in the treatment of GERD found that mosapride combined therapy is no more effective than PPI alone as a first-line therapy. Whether it is effective in PPI-refractory patients still remains to be determined;[@CIT0014] therefore, in this study, we aimed to investigate whether omeprazole plus mosapride combination therapy was more effective than omeprazole monotherapy in achieving symptom relief in PPI-refractory GERD patients using the frequency scale for symptoms of GERD (FSSG) questionnaire.

Methods {#S0002}
=======

Study design {#S0002-S2001}
------------

This was a prospective, randomized, double-blind, placebo-controlled trial conducted from January 2016 to January 2018 at the out-patient clinic of the Department of Medicine at Rajavithi Hospital, a tertiary referral center in Bangkok, Thailand. It was performed in accordance with the clinical principles laid down in the Declaration of Helsinki and informed consent was obtained from all the patients before their enrollment. The study protocol was reviewed and approved by the ethics committee of Rajavithi Hospital (clinicaltrials.in.th number, TCTR20190418003) and all participants provided written informed consent.

Participants {#S0002-S2002}
------------

The inclusion criteria were patients who (i) were aged more than 18 years; (ii) were diagnosed as having GERD by the presence at least twice a week of heartburn, deﬁned as a burning sensation in the retrosternal area, and/or regurgitation, deﬁned as the perception of ﬂow of reﬂuxed gastric content into the mouth or hypopharynx;[@CIT0001] and (iii) had received a standard dose of PPI for at least 8 weeks and still had FSSG total score (FSSG-TS) of eight points or more ([Table S1](#ST0001)), which is defined as having refractory GERD with substantial symptoms.[@CIT0015]

We excluded patients who (i) had a previous history of esophageal or gastrointestinal surgery apart from appendectomy and cholecystectomy; (ii) had severe cardiac or pulmonary disease, renal failure, liver cirrhosis or severe systemic illness; (iii) had an active Helicobacter pylori infection, determined by both the rapid urease test and histological identiﬁcation, or upper gastrointestinal diseases such as malignancy or peptic ulcers; (iv) were in a state of pregnancy or lactating; or (v) were hypersensitive or allergic to mosapride or omeprazole. Concomitant medications such as anti-hypertensive drugs were allowed if the dosage was not changed during the study period. Medications that affect esophageal motility or gastric acid secretion, eg prokinetics, PPIs, H2 receptor antagonists, cholinergic and⁄or anti-cholinergic agents, were discontinued 1 week before the start of the study.

The sample size was calculated using two independent means formula (two-tailed test), based on data from a previous report[@CIT0016] in which significant improvement in the FSSG-TS was observed after the addition of prokinetics for 4 weeks in PPI non-responsive NERD patients (FSSG-TS; initial 14.6±6.0 vs after 4 weeks of PPI plus prokinetics 7.7±5.2, *p*\<0.0001). The minimum required number of participants was calculated at 11 in each group in order to detect a signiﬁcant association with 80% power (β =0.20) and a 5% probability of type I error (2-sided) (α =0.05).

Endoscopic assessment {#S0002-S2003}
---------------------

Upper GI endoscopies had been conducted on all the patients within the 3-month period prior to their enrollment by two endoscopists (NK & AS). Endoscopic ﬁndings were graded using the Los Angeles (LA) classiﬁcation, with mucosal breaks classiﬁed as erosive GERD of LA grades A-D.[@CIT0017]

Grade A: One (or more) mucosal break no longer than 5 mm that does not extend between the tops of two mucosal folds

Grade B: One (or more) mucosal break more than 5 mm long that does not extend between the tops of two mucosal folds

Grade C: One (or more) mucosal break that is continuous between the tops of two or more mucosal folds but which involves less than 75% of the esophageal circumference

Grade D: One (or more) mucosal break which involves at least 75% of the esophageal circumference

Patients found to have no esophageal mucosal breaks were classiﬁed as having NERD. Sliding hiatal hernia was diagnosed when the apparent separation between the squamocolumnar junction and the diaphragmatic impression was greater than 2 cm as measured using the hash marks on the endoscope relative to the incisors.[@CIT0018]

Symptom assessment {#S0002-S2004}
------------------

Patients were evaluated for severity of symptoms using the FSSG questionnaire ([Table S1](#ST0001)). This is a validated instrument consisting of 12 questions developed speciﬁcally to evaluate GERD symptoms and their response to medical treatment, and it has been widely used in Japan and other countries.[@CIT0015],[@CIT0019],[@CIT0020] All patients were asked to supply answers to the questionnaire via a single investigator (NK) in order to control inter-observer variability in questioning consistency. Each question was rated using a ﬁve-point Likert scale, indicating the frequency of their symptoms as follows: never (0%) =0; occasionally (around 30% of the time) =1; sometimes (50%) =2; often (70%) =3; and always (100%) =4. The investigator (NK) was blinded to the type of medication that patients received while assessing their symptoms before, and 4 weeks after, treatment.

All patients were given a diary ([Table S2](#ST0002)) in which to record their symptoms every day. The diary comprised three questions regarding symptoms of: (i) heartburn; (ii) regurgitation; and (iii) night-time heartburn. The patients were instructed to record their symptoms, or lack of them, in the diary each day.

Randomization and study protocol {#S0002-S2005}
--------------------------------

After informed consent had been obtained, eligible patients were randomized into two treatment groups to receive omeprazole 20 mg (Miracid®, Berlin Pharmaceutical Industry Co. Ltd., Bangkok, Thailand) once daily plus either one tablet of mosapride 5 mg (Gasmotin®, Dainippon Sumitomo Pharmaceutical Co. Ltd., Osaka, Japan) or a placebo of similar appearance three times daily for 4 weeks. Randomization was performed using a computer-generated list of random numbers. An independent assistant gave mosapride or placebo to participants according to consecutive numbers kept in sealed envelopes. Use of drugs which could affect gastrointestinal motility and gastric acid secretion was not allowed during the study period.

The enrolled patients were evaluated using FSSG questionnaires at the beginning of the study and were given a diary in which to record their symptoms every day. After completing 4 weeks of medical therapy, a second FSSG questionnaire was completed, and any reported adverse events, including severity and duration of symptoms, were checked at this visit ([Figure 1](#F0001){ref-type="fig"}).Figure 1Participants flow diagram.

Outcomes {#S0002-S2006}
--------

Clinical symptoms were evaluated using FSSG-TS, FSSG-RS, and FSSG-DS before, and 4 weeks after, treatment. The primary outcome was to evaluate the difference in changes in FSSG scores between the two groups. The secondary outcome was to determine the number of symptom-free days (heartburn, regurgitation, and night-time heartburn) experienced by the patients during the study period, analyzed from their diary reports.

Statistical analysis {#S0002-S2007}
--------------------

Statistical analyses were performed using the SPSS software version 17.0 (SPSS Inc., Chicago, IL). Demographic data and baseline characteristics were analyzed using descriptive statistics, and categorical variables were compared using Chi-square test or Fisher exact test as appropriate. Continuous variables were compared using the Independent *t*-test or the Mann-Whitney U test. As the FSSG questionnaire was considered as an interval scale, FSSG scores were expressed as mean ± S.D. or median (min-max). All statistical examinations were two-tailed with a *p*-value \<0.05 defined as statistically significant.

Results {#S0003}
=======

Baseline characteristics of patients {#S0003-S2001}
------------------------------------

A total of 44 patients were enrolled in the study. Twenty-two were randomized into the omeprazole plus mosapride group (combination group) and the other 22 into the omeprazole plus placebo group (control group). All patients completed follow up and finally, 44 patients (n=44) were analyzed at the end of the study.

Demographic data and clinical characteristics of the two groups are shown in [Table 1](#T0003){ref-type="table"}. Age, gender, body mass index (BMI) and comorbid diseases were similar in the two groups. Lifestyle factors, including smoking, alcohol drinking and coffee consumption in the two groups were also comparable. Most of the subjects had NERD (91.0% in the combination group and 81.8% in the control group). The duration of symptoms in the combination group was 35.77 months (SD 21.25) and in the control group 25.68 months (SD 18.62). There were no significant differences in clinical characteristics or pre-treatment medication in the two groups.Table 1Baseline characteristics of patientsControl group (n=22)Combination group\
(n=22)*P*-valueAge, mean (SD), y53.14 (11.94)49.18 (13.84)0.316‡Female gender, n (%)16 (72.7)15 (68.2)0.741†BMI, mean (SD), kg/m^2^23.42 (5.02)24.16 (4.08)0.231‡Comorbid diseases Diabetes mellitus, n (%)4 (18.2)6 (27.3)0.472† Hypertension, n (%)7 (31.8)7 (31.8)1.000† Dyslipidemia, n (%)10 (45.5)8 (36.4)0.540†History of smoking1.000† Non-smoker/ex-smoker, n (%)22 (100)21 (95.5) Current smoker, n (%)0 (0)1 (0.5)History of alcohol drinking0.233† Non-drinker/ex-drinker, n (%)22 (100)19 (86.4) Current drinker, n (%)0 (0)3 (13.6)Coffee consumption, n (%)14 (63.6)10 (45.5)0.364†Endoscopic findings LA classification0.698† Grade A, n (%)2 (9.1)1 (4.5) Grade B, n (%)2 (9.1)1 (4.5) NERD, n (%)18 (81.8)20 (91.0) Sliding hiatal hernia, n (%)3 (13.6)6 (27.3)0.457†Duration of symptoms, mean (SD), months25.68 (18.62)35.77 (21.25)0.107‡Pre-treatment medication H2RA, n (%)1 (4.5)6 (27.3)0.095† Prokinetic agent, n (%)7 (31.8)7 (31.8)1.000† Antiflatulence, n (%)10 (45.5)11 (50.0)0.763† Antacid, n (%)12 (54.5)11 (50.0)0.763† Antispasmodic, n (%)2 (9.1)6 (27.3)0.240† Tricyclic antidepressant, n (%)3 (13.6)2 (9.1)1.000†[^1][^2]

Symptom improvement after treatment {#S0003-S2002}
-----------------------------------

Both treatment groups achieved similar significant symptomatic improvement after 4 weeks of therapy (FSSG-RS combination group −3.91±4.59 vs control group −3.45±4.77, *P*=0.595; FSSG-DS combination group −4.09±4.17 vs control group −2.23±3.13, *P*=0.109, and FSSG-TS combination group −8.00±7.18 vs control group −5.68±6.29, *P*=0.129) ([Figure 2](#F0002){ref-type="fig"}).Figure 2Reduction of the FSSG score after 4 weeks of treatment between the omeprazole monotherapy group and the omeprazole plus mosapride combination therapy group.

In the combination group, FSSG-TS decreased from 20.36±6.78 at baseline to 12.36±7.45 at week 4 (*P*\<0.001). Similarly, FSSG-TS in the control group decreased from 16.91±7.57 at baseline to 11.23±7.02 at week 4 (*P*=0.001). FSSG-RS scores in both groups decreased: from 10.36±3.35 to 6.45±3.57 (*P*\<0.001) in the combination group and from 8.91±4.64 to 5.45±3.20 (*P*=0.003) in the control group. Also, FSSG-DS scores in both groups improved: from 10.00±4.74 to 5.91±5.32 (*P*=0.001) in the combination group and from 8.00±4.15 to 5.77±4.70 (*P*=0.005) in the control group ([Table 2](#T0004){ref-type="table"}). There were no statistically significant differences in clinical symptoms of the two groups pre- and post-treatment ([Table 2](#T0004){ref-type="table"}).Table 2Clinical symptoms at pre-treatment and post-treatment between the omeprazole monotherapy group and the omeprazole plus mosapride combination therapy groupFSSG scorePre-treatment*P*-value‡Post-treatment*P*-value‡Control group\
(n=22)Combination group\
(n=22)Control group\
(n=22)Combination group\
(n=22)Reflux score8.91±4.6410.36±3.350.2405.45±3.206.45±3.570.334Dysmotility score8.00±4.1510.00±4.740.1445.77±4.705.91±5.320.929Total score16.91±7.5720.36±6.780.11811.23±7.0212.36±7.460.606[^3]

The number of symptom-free days {#S0003-S2003}
-------------------------------

In our study, all patients were given a diary in which to record their symptoms, including heartburn, regurgitation and night-time heartburn. Two patients in the combination group and one in the control group lost their diaries, so only 20 patients in the combination group and 21 patients in the control group were analyzed.

The secondary outcome was to assess the number of days free from heartburn, regurgitation, and night-time heartburn, and these data are shown in [Table 3](#T0005){ref-type="table"}. In the combination group, the patients had more regurgitation-free and night-time heartburn-free days than the patients in the control group, while patients in the control group had more heartburn-free days than their counterparts in the combination group, but these figures were not significantly different.Table 3The number of symptom-free days of the patients during the study periodSymptomsControl group (n=20)Combination group (n=21)*P*-value‡Heartburn-free days7.00 (1.00--14.00)6.50 (4.25--10.75)0.564Regurgitation-free days5.00 (1.50--15.00)5.50 (2.25--10.75)0.265Night-time heartburn-free days3.00 (0.00--11.00)7.00 (2.00--10.25)0.586[^4]

Safety concerns {#S0003-S2004}
---------------

No patients who had been treated for 4 weeks reported any serious side effects before discontinuing the use of either mosapride or omeprazole.

Discussion {#S0004}
==========

This randomized controlled trial of the efﬁcacy of combining mosapride or a placebo with a standard dose of PPI in treating PPI-refractory GERD patients showed that GERD symptoms were ameliorated from the baseline with both the combination therapy and PPI monotherapy, as demonstrated by the reduction in FSSG scores (FSSG- RS, FSSG-DS, and FSSG-TS) after 4 weeks of treatment. There was a trend towards greater improvement in the combination group compared with the control group, but the differences were not statistically signiﬁcant. In addition, we found no significant differences in the number of heartburn-free days, regurgitation-free days or night-time heartburn-free days between the two treatment groups.

The majority of our patients had NERD, and this is similar to other Asia-Pacific countries in which NERD accounts for 78--93% of all reﬂux disease.[@CIT0021] From a systematic review of the literature, the PPI symptomatic response pooled rate was only 36.7% in NERD patients and 55.5% in those with erosive reflux disease.[@CIT0022] Some investigators have postulated that delayed gastric emptying may be a contributory factor to PPI-refractoriness in NERD patients. Futagami et al[@CIT0012] evaluated gastric emptying in 20 healthy volunteers and in 44 PPI-refractory NERD patients before and after combined therapy of mosapride (15 mg/day) and omeprazole (20 mg/day) for 12 weeks. Gastric emptying in the PPI-refractory NERD patients was signiﬁcantly higher than that of healthy volunteers, and the administration of mosapride in addition to omeprazole improved reﬂux symptoms and gastric emptying in PPI-refractory NERD patients with delayed gastric emptying. On the other hand, a prokinetic agent had almost no effect on NERD patients with normal gastric motor function.

The difference between our results and those of the study by Futagami et al[@CIT0012] could be attributable to the different study populations; furthermore, the longer duration of their study protocol (our study lasted just 4 weeks while Futagami et al spanned 12 weeks) could be another factor that enhanced the efﬁcacy of combinations of prokinetics with PPI in the treatment of refractory reﬂux disease. There is supporting evidence that PPI is unstable at a low pH, retention of PPI in the stomach for a long time may result in an impaired acid-suppressive effect,[@CIT0023] so that rapid transit of PPI to the upper small intestine could be a benefit in PPI therapy. Arai et al[@CIT0023] reported that the addition of mosapride significantly improved the pharmacokinetic parameters of rabeprazole, particularly increased the peak plasma concentration (Cmax) and the area under the time-concentration curve (AUC). They concluded that co-administration of mosapride could have some favorable effect in PPIs-based therapy. Therefore, although it improved the pharmacokinetics of the PPI by prokinetics, it also required a prolonged duration of therapy of more than 4 weeks in refractory GERD patients to achieve a good response.

Another study by Miyamoto et al[@CIT0016] analyzed FSSG-TS, FSSG-RS, and FSSG-DS of PPI-refractory NERD patients, demonstrated that the addition of mosapride to PPI for 4 weeks in PPI-refractory NERD patients led to signiﬁcantly lower FSSG-TS, FSSG-RS and FSSG-DS at the end of treatment. They also found that younger age, constipation and dysmotility were the predictors of refractoriness to PPI therapy in NERD patients. These results suggest that a subset of patients with significant dysmotility and functional dyspepsia might beneﬁt from the addition of a prokinetic agent to PPI therapy. Although our study outcomes were similar to those of Miyamoto et al, our findings were not statistically significant, and this might be explained by the fact that our patients were more difficult to treat than Miyamoto et al population due to their higher pretreatment FSSG score (FSSG-TS in our study was 20.4 vs 14.6 in that of Miyamoto et al).[@CIT0019]

As a secondary outcome, our data showed that the effect of combination therapy on the number of symptom-free days in PPI-refractory GERD patients was not superior to that of PPI monotherapy. Most patients who have PPI failure are likely to originate from the NERD phenotype (86.4% in our study) which represents a heterogeneous population with complex, multifactorial underlying processes,[@CIT0022] compatible with the present study finding that the patients had symptom-free days in less than 50% of the treatment period, whether on standard dose PPI monotherapy or combination therapy.

The strength of the current study is that it was a randomized, double-blind, placebo-controlled trial. It compared the efficacy of omeprazole plus mosapride combination therapy with that of omeprazole monotherapy in PPI-refractory GERD patients, while previous reports[@CIT0012],[@CIT0016] were open-labeled trials with no control group, so that their positive results may be considered biased. Our study had several limitations, including the small number of patients available for sub-analysis to identify subgroups of patients, which conferred an advantage on combination therapy over PPI monotherapy. The duration of 4 weeks of our study may be another disadvantage that weakening the efficacy of combination therapy, the longer duration of combination therapy such as 12 weeks should be repeated study in these PPI-refractory GERD patients. Also, the diagnosis of GERD in the present study relied on the FSSG score and might have included patients prone to dyspepsia/dysmotility symptoms with concomitant functional bowel disorders that may be more difﬁcult to treat than typical GERD patients. Furthermore, our patients were not undergoing esophageal impedance-pH monitoring which recommended in patients with incomplete or lack of response to PPI therapy.[@CIT0024] So that we cannot exclude functional heartburn patients from our study population that may be the one-factor which impact on the study outcome.

Conclusion {#S0005}
==========

In summary, our results do not support the addition of mosapride to a standard dose of PPI in the PPI-refractory GERD patients. An appropriate therapeutic strategy for these patients needs to be further developed.
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[^1]: **Notes:** †Fisher's exact test or Chi-square test. ‡Mann-Whitney U-test or Independent *t*-test.

[^2]: **Abbreviations:** BMI, body mass index; LA classification, Los Angeles classiﬁcation; NERD, non-erosive reflux disease; H2RA, histamine 2 receptor antagonist; Combination group, omeprazole 20 mg once daily combined with mosapride 5 mg three times daily; Control group, omeprazole 20 mg once daily combined with placebo three times daily; SD, standard deviation.

[^3]: **Notes:** Data are shown as mean ± standard deviation. ‡Independent *t*-test.

    **Abbreviations:** FSSG, frequency scale for the symptoms of gastroesophageal reﬂux disease; Combination group, omeprazole 20 mg once daily combined with mosapride 5 mg three times daily; Control group, omeprazole 20 mg once daily combined with placebo three times daily.

[^4]: **Notes:** Data are shown as median (25th-75th interquartile range). ‡Mann-Whitney U-test.
